O8757
オフロキサシン
fluoroquinolone antibiotic
別名:
Dextrofloxacin
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C18H20FN3O4
CAS番号:
分子量:
361.37
UNSPSC Code:
51282956
PubChem Substance ID:
NACRES:
NA.76
MDL number:
biological source
synthetic
Quality Level
form
powder
solubility
1 M NaOH: soluble 50 mg/mL
antibiotic activity spectrum
Gram-negative bacteria, Gram-positive bacteria, mycobacteria
mode of action
DNA synthesis | interferes, enzyme | inhibits
storage temp.
2-8°C
SMILES string
FC1=C(C3=[c]4[n](cc([c]([c]4=C1)=O)C(=O)O)C(CO3)C)N2CCN(CC2)C
InChI
1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
InChI key
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
Gene Information
human ... CSNK2A1(1457), KCNH1(3756)
rat ... Gabra1(29705)
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
General description
化学構造：フルオロキノロン
Application
オフロキサシンは、広域スペクトルの抗菌活性を持つ合成フルオロキノロンです。本化合物はナリジクス酸類縁体です。網膜復位術施術前に患者に投与します。
Biochem/physiol Actions
オフロキサシンは、細菌のDNAジャイレースおよびトポイソメラーゼIVを阻害し、DNA複製と細胞分裂を阻害します。オフロキサシンはLytAを非活性型のEフォームから活性型のCフォームへ変換することが示されています 。本化合物は肺炎球菌の細胞壁分解病原性因子を阻害するキラル分子です。
Other Notes
容器は固く閉め、乾燥した、通気の良い場所で保管してください。
保管分類
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
O Cekiç et al.
The British journal of ophthalmology, 83(10), 1183-1185 (1999-09-30)
To assess the subretinal fluid (SRF) levels of ofloxacin following topical, oral or combined administration. 31 patients undergoing conventional retinal reattachment surgery were randomly assigned to three groups. Nine patients received topical ofloxacin, 11 patients received oral ofloxacin, and the
Carlos Fernández-Tornero et al.
The Journal of biological chemistry, 280(20), 19948-19957 (2005-03-17)
The search for new drugs against Streptococcus pneumoniae (pneumococcus) is driven by the 1.5 million deaths it causes annually. Choline-binding proteins attach to the pneumococcal cell wall through domains that recognize choline moieties, and their involvement in pneumococcal virulence makes
S Güniz Küçükgüzel et al.
European journal of medicinal chemistry, 42(7), 893-901 (2007-04-10)
Three novel series of 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid derivatives namely 4-substituted-1,2,4-triazoline-3-thiones (4a-g); 2-substituted-1,3,4-thiadiazoles (5a-g) and 2-substituted-1,3,4-oxadiazoles (6a-g) have been synthesized. Twenty-one of the newly synthesized compounds were tested against various bacteria, fungi, yeast species and virus. In addition, we have replaced the
Andrea Von Groll et al.
Antimicrobial agents and chemotherapy, 53(10), 4498-4500 (2009-08-19)
This study evaluated cross-resistance of Mycobacterium tuberculosis strains to ofloxacin, moxifloxacin, and gatifloxacin and investigated the presence of mutations in gyrA and gyrB. Fluoroquinolone susceptibilities were determined for 41 M. tuberculosis strains by the proportion method on 7H11, and MICs
Cécile Denève et al.
Antimicrobial agents and chemotherapy, 53(12), 5155-5162 (2009-10-07)
Recent outbreaks of Clostridium difficile infection have been related to the emergence of the NAP1/027 epidemic strain. This strain demonstrates increased virulence and resistance to the C-8-methoxyfluoroquinolones gatifloxacin and moxifloxacin. These antibiotics have been implicated as major C. difficile infection-inducing
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）